Skip to content

Bayoclin

Active Private limited companyfounded 2021active for 5 yearsAvenue de Vaillampont 13, 1402 NivellesKBO/BCE: BE 0776.573.783

Lifetime

4 annual accounts with figures on one time axis
peak of €279,684 in 2024
€240,138▼ 14.1%
peak of €212,792 in 2024
€181,583▼ 14.7%
peak of €530,132 in 2024
€232,832▼ 56.1%
€36,931▲ 191%
Board1 name since 2021
1 director
Documentsfilings and deeds
27-04-202695 days before the deadline
2025micro format
Gross margin from €279,684 to €240,138Dividend €478,883Equity from €530,132 to €232,832Debts from €12,681 to €36,931Cash from €45,963 to €73,268

Key points

from the 2025 annual accounts

Equity

€232,832 ▼ 56.1%
530,1322024+181,583Profit-478,883Dividend232,8322025

Bayoclin paid out €478,883 in dividends. That is 264% of the 2025 profit.

Turnover

≈ €590,000 estimated

The micro format states no turnover.

Liquidity

6.94 was 41.44 in 2024

Short-term debts rose from €12,681 to €36,931.

Filings

4 annual accounts since 2022
AprilJune31 JulyOctober2022202320242025

The last four annual accounts were filed 47 to 95 days before the end of the period.

Position in the sector

€181,583

Higher net result than 91% of companies in research and development. The sector median is €23,595, over 670 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 26,977 companies had the same profile as Bayoclin has now. Each dot stands for 68 companies, two years later.

94.9%
were still trading
3.5%
stopped another way
1.6%
went bankrupt
  • Micro
  • 5 to 10 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 26,977 companies, not a prediction for Bayoclin. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 27-10-2021
  • all the sharesdeed of 14-06-2023
Board & ownership

Recent changes

Registered office moved from Celles to Thines The registered office moved from Rue Leclercqz 28 à 7760 CELLES to Avenue de Vaillampont, 13 à 1402 THINES · holds all the shares · General meeting of 05-05-2023 · Gazette deed
Incorporation Founding capital of €2,500, 100 shares · Founded by · appointed as director · published on 29-10-2021 · Gazette deed
First establishment At the time the registered office was still in Celles, Rue Leclercqz 28.
All 12 events

Comparable companies

same main activity, similar in size and age
Company
Bayoclin Nivelles €269,763 €240,138 86.3% -
BONT Kasterlee €307,284 €152,933 2.0% -
CBaBC Destelbergen €249,523 €132,478 91.3% -
GMPharm Perwez €215,626 €73,251 81.2% -
OPERO Grimbergen €225,981 €168,579 2.2% -
Thomas De Beer Consulting Deinze €252,275 €108,766 64.2% -
HiSta Research Consult Sint-Niklaas €297,994 €109,563 46.9% -

These companies have the same main activity as Bayoclin: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €216,000 and €307,000, founded between 2021 and 2022.

Official details

Source: KBO
Status
Active since 27-10-2021Normal situation
Activity
Research and development on biotechnologyNACE 72101
Establishment unit
2.324.524.0341402 Nivelles, registered on 27-10-2021
Financial year end
31 December
Peppol
Not found in the Peppol Directory
Company details

Annual accounts 2025

€269,763▼ 50.3%
Filing
Filed on 27-04-2026, 95 days before the end of the filing period
Financials

Insights on Bayoclin

Bayoclin files the micro format. That format states no turnover. The gross margin rose from €187,704 in 2022 to €240,138 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about Bayoclin

What is the company number of Bayoclin?
The company number of Bayoclin is 0776.573.783. The VAT number is the same number with BE in front: BE 0776.573.783.
Where is Bayoclin based?
The registered office is at Avenue de Vaillampont 13, 1402 Nivelles.Company details
What does Bayoclin do?
According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
What is the legal form of Bayoclin?
Bayoclin is a private limited company (BV).
When was Bayoclin founded?
Bayoclin was founded on 27-10-2021.
Is Bayoclin still active?
Yes, Bayoclin is an active enterprise in the KBO register.
What is the turnover of Bayoclin?
The turnover in financial year 2025 is about €590,000. This figure is estimated from the gross margin of €240,138 and 2,454 comparable companies of the same size. It probably lies between €400,000 and €930,000. It is a rough estimate.Financials
Is Bayoclin profitable?
In financial year 2025, Bayoclin made a profit of €181,583.
Where can I find the annual accounts of Bayoclin?
Bayoclin filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Bayoclin due?
Bayoclin must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.